Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Brequinar
Potential treatment - pre-clinical evidence Experimental Antiviral Jul/13/2020
PT150
Potential treatment - pre-clinical evidence Experimental Antiviral Jul/13/2020
cnCoVP-7
Potential treatment - theoretical effect Experimental Antiviral Jul/09/2020
cnCoVP-4
Potential treatment - theoretical effect Experimental Antiviral Jul/09/2020
cnCoVP-3
Potential treatment - theoretical effect Experimental Antiviral Jul/09/2020
N14-R7
Potential treatment - pre-clinical evidence Experimental Antiviral Jul/07/2020
NCGC00411883-01
Potential treatment - pre-clinical evidence Experimental Antiviral Jul/01/2020
Rigosertib
Potential treatment - pre-clinical evidence Experimental Other treatment Jun/27/2020
Kinetin riboside
Potential treatment - pre-clinical evidence Experimental Other treatment Jun/27/2020
Cilomilast
Potential treatment - pre-clinical evidence Experimental Other treatment Jun/27/2020
Eicosatetraynoic acid
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
Deforolimus
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
HG-5-88-01
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
OMDM-2
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
beta-CCM
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
Dexanabinol
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
Triciribine
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
Flubendazole
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
Quinoclamine
Potential treatment - theoretical effect Experimental Other treatment Jun/27/2020
YM201636
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/25/2020